Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Bullish +72

Becton Dickinson stock holds near its yearly high - ad-hoc-news.de

AI-generated analysis

πŸ“ˆ Becton Dickinson reported Q3 fiscal 2026 revenue of USD 5.0 billion, marking a 5.4% increase compared to the same period last year.

πŸ’° The company achieved an adjusted EPS of USD 3.23 for the quarter, significantly higher than the GAAP diluted EPS of USD 1.64.

πŸ“Š Stock price reached USD 188.13 on September 1, 2026, trading just below its 52-week high of USD 193.07.

πŸ’΅ BDX declared a quarterly dividend of USD 1.05 with a record date of September 9, 2026 and payment on September 30, 2026.

🏒 The company operates in the Health Care sector under the Medical Instruments and Supplies industry within the S&P 500.

πŸ“‰ Revenue growth was driven by core segments including consumables, devices, and diagnostics.

πŸ” Adjusted earnings exceeded GAAP earnings by USD 1.59 per share due to non-recurring items affecting the bottom line.

Bullish Signals
  • Becton Dickinson achieved a robust 5.4% year-over-year revenue increase in Q3 fiscal 2026, reaching USD 5.0 billion.
  • The company reported an adjusted EPS of USD 3.23, demonstrating strong underlying profitability despite GAAP figures being lower.
  • Stock price climbed to USD 188.13, trading near its yearly high and showing resilience in the Health Care sector.
  • BDX maintains a consistent commitment to shareholders with a quarterly dividend of USD 1.05 scheduled for payment.
Risk Factors
  • The significant gap between adjusted EPS (USD 3.23) and GAAP diluted EPS (USD 1.64) indicates that non-recurring items continue to impact the reported earnings line.
  • Stock price traded 2.5% below its 52-week high, suggesting some caution or lack of immediate momentum despite strong quarterly results.
Full Analysis
Becton Dickinson and Company (BDX) reported strong third-quarter fiscal 2026 results, with revenue reaching USD 5.0 billion, representing a 5.4% year-over-year increase. The company's adjusted earnings per share stood at USD 3.23, significantly outpacing the GAAP diluted EPS of USD 1.64 due to non-recurring items. This financial performance helped push the stock price to USD 188.13 on September 1, 2026, positioning it near its yearly high of USD 193.07. The company continues to focus on its core medical technology business, which includes consumables, devices, and diagnostics. BDX maintains a consistent dividend policy with a quarterly payout of USD 1.05, set for payment on September 30, 2026. With a market capitalization of approximately USD 51.84 billion, the stock remains a significant component of the S&P 500 within the Health Care sector. Analysts and investors are noting the substantial gap between adjusted and GAAP earnings, highlighting that non-recurring items still influence the reported bottom line. Despite this, the revenue crossing the USD 5 billion threshold and the solid year-over-year growth suggest continued operational strength in the medical instruments and supplies industry.